Covered recipient · General Payments record
DARKO ERNESTO QUISPE OROZCO
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2022–2024
$609.18
- Reported across 24 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $387.27 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| UCB, Inc. | $147.12 | 11 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $140.33 | 2 |
| Teva Pharmaceuticals USA, Inc. | $50.91 | 3 |
| EISAI INC. | $48.91 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Eisai Inc. | $24.78 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110739553 | CMS |
| Eisai Inc. | $24.13 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110739555 | CMS |
| Novartis Pharmaceuticals Corporation | $116.72 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087340919 | CMS |
| Novartis Pharmaceuticals Corporation | $23.61 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087340905 | CMS |
| Teva Pharmaceuticals USA, Inc. | $17.09 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151681093 | CMS |
| Teva Pharmaceuticals USA, Inc. | $16.91 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151681115 | CMS |
| Teva Pharmaceuticals USA, Inc. | $16.91 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151681130 | CMS |
| UCB, Inc. | $18.38 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143101789 | CMS |
| UCB, Inc. | $15.77 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143101791 | CMS |
| UCB, Inc. | $2.22 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143101793 | CMS |
| UCB, Inc. | $25.46 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143101795 | CMS |
| UCB, Inc. | $1.61 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143101797 | CMS |
| UCB, Inc. | $15.66 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143101799 | CMS |
| UCB, Inc. | $1.77 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143101801 | CMS |
| UCB, Inc. | $22.97 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143101803 | CMS |
| UCB, Inc. | $26.17 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143101805 | CMS |
| UCB, Inc. | $1.66 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143101807 | CMS |
| UCB, Inc. | $15.45 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143101809 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.